Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Use advanced search instead (articles only)
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Cardiovascular Conditions
Vol. 3, Issue 1, 2015
October 26, 2016 EDT
Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
Yaariv Khaykin
,
Peter J. Mallow
,
John A. Rizzo
,
Atul Verma
,
Lauren Chun
,
Shelby Olesovsky
,
Matthew R. Reynolds
,
markov model
cost-utility
canada
atrial fibrillation
cost-effectiveness
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9837
JHEOR
1.
Khaykin Y, Mallow PJ, Rizzo JA, et al. Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.
JHEOR
. 2016;3(1):1-12.
doi:10.36469/9837
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats